**AUB KQ1 Evidence Table (Reference ID #1190)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Hall et al., 1987  **Country:**  United Kingdom  **Enrollment** **period:**  NR  **Intervention** **setting:**  Outpatient clinics  **Funding:**  NR  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT (crossover)  **Blinding:**  Patients, clinicians | **Intervention:**  Naproxen loading dose 550 mg followed by 275 mg every 6 hours for 5 days  **Comparator:**  Mefenamic acid 500 mg every 8 hours  **Groups:**  **G1:** Naproxen in phase 1 and mefenamic acid in phase 2  **G2:** Mefenamic acid in phase 1 and naproxen sodium in phase 2  **Ga:** Naproxen  **Gb:** Mefenamic acid  **Followup:**  6 cycles | **Inclusion criteria:**   * Aged 18 years through menopause   Dysfunctional uterine bleeding  MBL of >80ml confirmed in 2 initial control cycles  **Exclusion criteria:**  Pelvic inflammation  Uterine fibroids  Local disease  Gross cyclic irregularities  Taking NSAIDs, steroids  Drug sensitivity  Disorder requiring medical care  Poor clinic attendance  **N at enrollmenta:**  **G1:** 19  **G2:** 19  **N at follow-up:**  **G1:** 17  **G2:** 16  **Age, mean years ± SD:**  **G1:** 40.5 ± 3.6  **G2:** 38.1 ± 4.7  **BMI:**  NR  **Parity:**  NR  **Race/ethnicity:**  NR  **Menorrhagia duration, mean number of months ± SD:**  **G1:** 55.8 ± 53.0  **G2:** 45.0 ± 41.4 | **Bleeding**  MBL measured using the alkaline hematin method, median ml (range):  **G1:** 118.5 (68, 186)  **G2:** 129.3 (58, 369)  **G1 vs. G2:** p=0.92  Bleeding days per cycle, mean ± SD:  **G1:** 8.0 ± 2.8  **G2:** 6.6 ± 1.5  Hemoglobin, mean g/dl ± SD:  **G1:** 13.0 ± 1.0  **G2:** 12.1 ± 1.70  **G1** **vs.** **G2:** p=0.06  Serum iron, mean μmol/l ± SD:  **G1:** 14.3 ± 5.96  **G2:** 11.8 ± 7.95  Tampons used, mean:  **G1:** 31  **G2:** 32 | **Bleeding**  MBL measured using the alkaline hematin method (with slight modification to accommodate bulky material at phase 1), median ml (range):  **G1:** 67.0 (15, 151)  **G2:** 68.0 (22, 381)  **G1 vs. BL:** p<0.001  **G2 vs. BL:** p<0.001  **G1** **vs. G2:** p=0.84  MBL at treatment phase 2,  **G1**: 64.5 (22-135)  **G2**: 67.3 (18-357)  **G1 vs. BL:** p<0.001  **G2 vs. BL:** p<0.001  **G1** **vs. G2:** p=0.69  Bleeding days per cycle, mean, p value:  **G1a:** 6.4  **G1b:** 5.9  **G2a:** 5.9  **G2b:** 6.0  **G1a vs. BL:** p=0.01  **G1b vs. BL:** p=0.01  **G2a vs. BL:** p=0.004  **G2b vs. BL:** p=0.03  Tampons used, mean:  **G1a:** 23  **G1b:** 23  **G2a:** 25  **G2b:** 25  **G1a vs. BL:** p=0.003  **G1b vs. BL:** p=0.005  **G2a vs. BL:** p=0.003  **G2b vs. BL:** p=0.017  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  NR  **Adverse events, n:**  Any side effects:  **Ga:** 18  **Gb:** 15  Gastrointestinalb:  **Ga:** 13  **Gb:** 6  Central nervous system symptomsc:  **Ga:** 5  **Gb:** 6  Otherd:  **Ga:** NR  **Gb:** NR | **Overall quality:**  Fair  **Risk of bias:**  Randomization:  Low  Allocation concealment:  Low  Selective reporting:  Low  Blinding patients/personnel:  Low  Blinding outcome assessment:  Low  Incomplete outcome reporting:  High  Other:  Low |

**Table Notes**: a 50 patients at baseline, 9 withdrew before treatment, 1 withdrew in first treatment phase, 5 had <80 cc mbl, so 35 analyzed; b Included nausea, diarrhea, abdominal discomfort and anorexia; c Complaints of light headedness, dizziness, tiredness and headache; d A small number of patients in each treatment group noted weight increase, limb pain, pelvic discomfort, and post menstrual discharge.